# Dabigatran

## Pradaxa 150mg

##### 臨採

| TAH Drug Code      | [**OPR150**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OPR150)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation: adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily, with or without food. For prophylaxis of venous thrombosis of hip replacement surgery, starting 75mg within 1-4 hours after the operation, then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days, then 150mg twice a day for 6 months. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Pathological bleeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Gastrointestinal: Dyspepsia (11%; includes abdominal discomfort/pain, epigastric discomfort) GI hemorrhage (<6%), gastritis-like symptom Hematologic: Bleeding (8% to 33%; major: <6%) Anemia (1% to 4%) hematoma (1% to 2%) hemoglobin decreased (1% to 2%) hemorrhage (postprocedural or wound: 1% to 2%) Hepatic: ALT increased (>3 x ULN: 2% to 3%) Renal: Hematuria (1%) Miscellaneous: Wound secretion (5%), postprocedural discharge (1%)                                                                                                                                                         |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## Pradaxa 110mg

| TAH Drug Code      | [**OPRAD**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OPRAD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of venous thromboembolic events in patients who have undergone elective total hip or knee replacement surgery; stroke & systemic embolism in patients w/ atrial fibrillation in whom anti-coagulation is appropriate.                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation:adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily, with or without food. For prophylaxis of venous thrombosis of hip replacement surgery, starting 75mg within 1-4 hours after the operation, then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days, then 150mg twice a day for 6 months. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Severe renal impairment (CrCl <30 mL/min), haemorrhagic manifestations, bleeding diathesis or patients w/ spontaneous or pharmacological impairment of haemostasis, lesions at risk of clinically significant bleeding, concomitant treatment w/ strong p-glycoprotein (p-gp) inhibitors eg ketoconazole.                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | Anemia, GI haemorrhage, haematoma, hematuria, wound haemorrhage; wound secretion, postprocedural haematoma, postprocedural haemorrhage, post-op anemia, traumatic haematoma, postprocedural discharge; ALT ≧3 x ULN, decreased haemoglobin. Epistaxis, urogenital haemorrhage; abdominal pain, diarrhoea, dyspepsia, nausea.                                                                                                                                                                                                                                                                            |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

